Iceland· IS-EU/1/20/1457/001
Xenleta
A lefamulin product containing lefamulinum inn, registered in Iceland by VENIPHARM. The same ATC class is registered in 9 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Lefamulin is registered in 9 of 19 countries.
Countries holding a registration under ATC J01XX12 (lefamulin), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 6 of them publish a price we can compare per daily dose
Lefamulin · ATC J01XX12
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Lefamulinum INN
- Manufacturer
- VENIPHARM
- Country
- Iceland (IS)
- ATC code
- J01XX12
- ATC class
- Lefamulin
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
362 interactions on record for lefamulin.
Graded by severity as the source publishes them — 133 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lefamulin · interactions on record
362 records
- 133 severe
- 227 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lefamulin in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumXenleta 150 mgVenipharm
- FinlandXenletaVenipharm
- IrelandXenleta 150 mg concentrate for solution for infusionNabriva Therapeutics Ireland Designated Activity Company
- PolandXenletaNabriva Therapeutics Ireland DAC
- SwedenXenleta 150 mg Koncentrat och vätska till infusionsvätska, lösningVENIPHARM
- CzechiaXENLETAVENIPHARM S.A.S, Saint Cloud
- United StatesXenletaMeitheal Pharmaceuticals Inc.
- NetherlandsXenleta 150 mg concentraat en oplosmiddel voor oplossing voor infusieVenipharm
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Xenleta
- Norway · Xenleta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3d2d9d4e-fee4-4925-8b76-8ce526c9b5a4 GET /v1/drugs/3d2d9d4e-fee4-4925-8b76-8ce526c9b5a4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni og leysir, lausn",
"source": "lyfjastofnun",
"atc_raw": "J01XX12",
"marketed": false,
"strength": "150 mg",
"ma_number": "EU/1/20/1457/001",
"substance": "Lefamulinum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "44039"
}See everything about lefamulin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.